Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multi-center, Phase 2 Clinical Study of an Autologous Anti-CD19/CD20 Chimeric Antigen Receptor T-Cell Therapy, Prizloncabtagene Autoleucel (Prizlon-cel), for the Treatment of Relapsed or Refractory Large B-Cell Lymphoma

NCT07875413 is registered in ClinicalTrials.gov with AbelZeta Inc. as lead sponsor.

NCT NCT07875413
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07875413 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multi-center, Phase 2 Clinical Study of an Autologous Anti-CD19/CD20 Chimeric Antigen Receptor T-Cell Therapy, Prizloncabtagene Autoleucel (Prizlon-cel), for the Treatment of Relapsed or Refractory Large B-Cell Lymphoma
Lead sponsor
AbelZeta Inc.
Phase
Phase 2
Overall status
Not yet recruiting
Start date
May 31, 2027
Completion date
December 31, 2030
Enrollment
55 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

diffuse large b cell lymphoma (dlbcl), fl, hgbl, hgbl with myc and bcl2 and/or bcl6 rearrangements, high grade b cell lymphoma, large b cell lymphoma, lbcl, pmbcl, primary mediastinal b cell lymphoma, relapse diffuse large b cell lymphoma, transformed follicular lymphoma (tfl)